Insider Selling: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Director Sells $32,130.00 in Stock

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Director Stephen Ray Mitchell sold 7,000 shares of the stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $4.59, for a total transaction of $32,130.00. Following the completion of the transaction, the director now owns 97,082 shares of the company’s stock, valued at approximately $445,606.38. The trade was a 6.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Vanda Pharmaceuticals Price Performance

Shares of Vanda Pharmaceuticals stock opened at $4.53 on Friday. Vanda Pharmaceuticals Inc. has a 1 year low of $3.81 and a 1 year high of $6.37. The firm’s 50-day moving average is $4.35 and its 200 day moving average is $4.54. The stock has a market cap of $266.95 million, a price-to-earnings ratio of -6.04 and a beta of 0.66.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.05. Vanda Pharmaceuticals had a negative net margin of 21.98% and a negative return on equity of 8.30%. The business had revenue of $50.04 million during the quarter, compared to analysts’ expectations of $45.13 million. On average, equities analysts expect that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current fiscal year.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Quantinno Capital Management LP purchased a new stake in Vanda Pharmaceuticals during the 4th quarter valued at $48,000. PVG Asset Management Corp purchased a new position in shares of Vanda Pharmaceuticals in the first quarter worth $48,000. Linden Thomas Advisory Services LLC purchased a new position in shares of Vanda Pharmaceuticals in the first quarter worth $49,000. XTX Topco Ltd bought a new position in shares of Vanda Pharmaceuticals during the fourth quarter valued at $69,000. Finally, Nations Financial Group Inc. IA ADV purchased a new stake in shares of Vanda Pharmaceuticals during the first quarter valued at $67,000. 88.14% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have weighed in on VNDA. Wall Street Zen upgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, June 14th. Cantor Fitzgerald restated an “overweight” rating and issued a $13.00 price target on shares of Vanda Pharmaceuticals in a research note on Wednesday, May 14th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Vanda Pharmaceuticals in a research report on Wednesday, May 7th.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.